Summary
Outcomes from the Abatacept Versus Adalimumab Head-to-Head [AMPLE; NCT00929864] trial demonstrated comparable efficacy between subcutaneous abatacept and adalimumab on background methotrexate. This article discusses key efficacy and safety results from the trial.
- Rheumatoid Arthritis
- Rheumatology Clinical Trials
- © 2012 MD Conference Express®
Tools
Head-to-Head Biologics Trial Shows No Difference between Abatacept and Adalimumab
Permalink:
